Immuneering on track to dose first patient in pancreatic cancer trial in 2026

Immuneering (IMRX) announced that it is on track to dose the first patient in its planned global Phase 3 registrational trial in first line pancreatic cancer patients in mid-2026, evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel, compared with gemcitabine and nab-paclitaxel alone. The company completed its End-of-Phase 2 interactions with the FDA and received scientific advice from the European Medicines Agency. Immuneering achieved alignment with both agencies on the key elements of the company’s proposed Phase 3 trial. The company expects to dose the first patient in mid-2026 and share topline results from the trial in mid-2028. Immuneering also reiterated management’s belief that the company’s current cash and cash equivalents, based on current operating plans, are sufficient to fund operations into 2029.